The AML Prognostic Panel (3 Markers) is designed to assess key genetic mutations that influence prognosis and treatment response in Acute Myeloid Leukemia. Metropolis Healthcare uses advanced molecular techniques to deliver accurate, clinically relevant insights that support personalised cancer management.
Price:
Rs. 12,500.00
Sample Type: EDTA Whole Blood
Fasting Not Requierd
Frequently Asked Questions (FAQ's):
What does the AML Prognostic Panel (3 Markers) include at Metropolis Healthcare?
It analyses three important genetic markers associated with prognosis, treatment response, and risk stratification in AML.
How does Metropolis Healthcare perform this AML marker test?
Highly sensitive molecular methods such as PCR-based assays or sequencing are used to detect specific gene mutations.
Who should undergo the AML Prognostic Panel at Metropolis Healthcare?
Patients diagnosed with Acute Myeloid Leukemia who require prognostic evaluation or treatment planning should take this test.
Why are these three prognostic markers important?
They help determine disease risk category, predict treatment success, and guide the choice of targeted therapies.
Is any special preparation needed for this test?
No preparation is required; a bone marrow or blood sample recommended by the clinician is sufficient.
How do the results help in AML management?
The results assist oncologists in selecting appropriate treatment strategies and predicting disease progression.
How long does Metropolis Healthcare take to provide the report?
Results are typically available within several working days, depending on the complexity of the analysis.
Is the test reliable?
Yes. Metropolis Healthcare follows strict quality protocols and uses validated molecular platforms for precise mutation detection.